DDInter998 DDInter1760
Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of _Streptomyces avermitilis_. Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro­-25-(1-methylethyl)avermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1b</sub>). Ivermectin is mainly used in humans in the
Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment. Neuroendocrine cells are cells that secrete regulatory peptides and biogenic amines in response to chemical, neural, or other types of stimuli. Neuroendocrine tumors (NET) arising from these cells can therefore secrete chemical mediators into the bloodstream to cause side effects in distant sites, a phenomenon called carcinoid syndrome. The most common peptides and amines secreted by NET are histamines, tachykinins, kallikrein, and serotonin. Overexposure to serotonin can cause severe diarrhea, one of the main clinical symptoms of carcinoid syndrome. Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET. The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.
Ivermectin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ivermectin {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ivermectin {u} (Compound) upregulates {v} (Gene) XPOT
XPOT {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ivermectin {u} (Compound) downregulates {v} (Gene) MCM3
MCM3 {u} (Gene) is downregulated by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ivermectin {u} (Compound) downregulates {v} (Gene) RPS6KA1
RPS6KA1 {u} (Gene) is bound by {v} (Compound) Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ivermectin {u} (Compound) downregulates {v} (Gene) RPS6KA1
RPS6KA1 {u} (Gene) is upregulated by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ivermectin {u} (Compound) downregulates {v} (Gene) AURKA
AURKA {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ivermectin {u} (Compound) downregulates {v} (Gene) PSMD2
PSMD2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ivermectin {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telotristat ethyl
Ivermectin {u} (Compound) causes {v} (Side Effect) Abdominal discomfort
Abdominal discomfort {u} (Side Effect) is caused by {v} (Compound) Octreotide
Octreotide {u} may lead to a major life threatening interaction when taken with {v} Telotristat ethyl
Ivermectin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ivermectin (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ivermectin (Compound) upregulates XPOT (Gene) and XPOT (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ivermectin (Compound) downregulates MCM3 (Gene) and MCM3 (Gene) is downregulated by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ivermectin (Compound) downregulates RPS6KA1 (Gene) and RPS6KA1 (Gene) is bound by Sunitinib (Compound) and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ivermectin (Compound) downregulates RPS6KA1 (Gene) and RPS6KA1 (Gene) is upregulated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ivermectin (Compound) downregulates AURKA (Gene) and AURKA (Gene) is bound by Crizotinib (Compound) and AURKA (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ivermectin (Compound) downregulates PSMD2 (Gene) and PSMD2 (Gene) is bound by Bortezomib (Compound) and PSMD2 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ivermectin (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ivermectin (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Octreotide (Compound) and Octreotide may lead to a major life threatening interaction when taken with Telotristat ethyl